Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $4,581,551,000 | $4,263,762,000 | $4,027,478,000 | $3,569,006,000 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Cost of Goods Sold | $1,580,217,000 | $1,431,505,000 | $1,244,072,000 | $1,106,846,000 |
| Gross Profit | $3,001,334,000 | $2,832,257,000 | $2,783,406,000 | $2,462,160,000 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| R&D Expenses | $730,227,000 | $729,924,000 | $633,325,000 | $526,087,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,104,766,000 | $1,053,819,000 | $997,309,000 | $886,361,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $823,755,000 | $834,439,000 | $662,267,000 | $588,867,000 |
| Operating Expenses | $2,658,748,000 | $2,618,182,000 | $2,292,900,000 | $2,001,315,000 |
| Operating Income | $342,586,000 | $214,075,000 | $490,505,000 | $460,844,000 |
| % Margin | 7.5% | 5% | 12.2% | 12.9% |
| Other Income/Exp. Net | -$167,502,000 | -$161,284,000 | -$115,415,000 | -$158,273,000 |
| Pre-Tax Income | $175,084,000 | $52,791,000 | $375,090,000 | $302,571,000 |
| Tax Expense | $66,941,000 | -$91,406,000 | $58,052,000 | $72,405,000 |
| Net Income | $107,928,000 | $144,067,000 | $317,017,000 | $230,059,000 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS | 34.17 | 46.05 | 102.15 | 73.57 |
| % Growth | -25.8% | -54.9% | 38.8% | – |
| EPS Diluted | 33.62 | 45.58 | 100.97 | 72.94 |
| Weighted Avg Shares Out | 3,210,710 | 3,128,900 | 3,103,618 | 3,127,002 |
| Weighted Avg Shares Out Dil | 3,210,710 | 3,160,686 | 3,139,744 | 3,154,338 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,638,000 | $78,097 | $5,508,000 | $4,591,000 |
| Interest Expense | $137,311,000 | $1,062,438 | $116,973,000 | $122,432,000 |
| Depreciation & Amortization | $761,396,000 | $644,461,000 | $664,400,000 | $583,151,000 |
| EBITDA | $1,210,512,000 | $1,143,936,000 | $1,284,067,000 | $1,183,213,000 |
| % Margin | 26.4% | 26.8% | 31.9% | 33.2% |